MONTREAL, September 11, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that Guy Sauvageau, President and CEO, will present a company update at the annual Cell & Gene Meeting on the Mesa to be held October 2-4 in Carlsbad, California.
ExCellThera’s lead technology, ECT-001, is a combination of a small molecule and an optimized culture system. The technology, capable of expanding stem and immune cells exponentially in as little as seven days, is used in novel curative cell therapies for patients with blood cancers and other hematologic malignancies, allowing more rapid engraftment, greatly reduced incidence of transplant-related mortality, low risk of chronic graft-versus-host disease and low risk of relapse, resulting in better outcomes for patients. ECT-001 has received FDA orphan drug designation (ODD) for the prevention of graft-versus-host disease and regenerative medicine advanced therapy (RMAT) designation in the treatment of hematologic malignancies.
The following are specific details regarding ExCellThera’s presentation at the conference:
Event: 2019 Cell & Gene Meeting on the Mesa
Date: October 2, 2019
Time: 1:45pm PT
Location: Cognate Bioservices Ballroom, Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, CA 92011
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring more than 80 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers. Complimentary attendance at this event is available for credentialed investors and members of the media only. www.meetingonthemesa.com
A live webcast of this presentation will be available at: http://www.meetingonthemesa.com/webcast http://www.meetingonthemesa.com/webcast/and will also be published on the conference website shortly after the event.
About ExCellThera Inc.
ExCellThera is an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel one-time curative therapies for patients with hematologic malignancies, autoimmune and other diseases. ExCellThera’s lead solution combines a proprietary small molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical trials. excellthera.com
